RAK cell therapy for advanced stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new type of immune cell therapy called RAK cells for people with late-stage stomach cancer that has spread and stopped responding to standard treatments. The goal is to see if it is safe and helps control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must have stage IV stomach cancer or cancer where the stomach meets the esophagus that has spread to other organs like the liver, lungs, or lymph nodes.
- You must have tried at least one prior chemotherapy, targeted therapy, or immunotherapy, and it didn't work or the cancer got worse.
- You must be well enough to care for yourself, even if you need to stay in bed less than half the day (ECOG 0-3).
- Your doctor must be able to measure your tumors with a CT or MRI scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares three different treatment combinations for advanced stomach cancer that hasn't spread to the brain and is HER2-negative. It includes an immunotherapy drug (sintilimab) with different chemotherapy backbones, and one option adds a targeted therapy (lenvatinib). The goal is to see which combination works best and has acceptable side effects.
This trial tests a combination of three drugs — trifluridine/tipiracil (a chemotherapy pill), bevacizumab (avastin, a targeted therapy), and camrelizumab (an immunotherapy) — as a later treatment option for people with advanced stomach cancer who have already tried other therapies. It may help patients whose cancer has not responded to previous treatments.
This trial tests an experimental therapy for people with advanced stomach or gastroesophageal junction cancer that has not responded to at least two prior treatments. The therapy targets a specific protein (CLDN18.2) found on cancer cells. The goal is to see if this approach can help control the disease.
This trial tests a new drug called CT0494BCP for advanced stomach cancer that has not responded to previous treatments. The drug targets a protein called CLDN18.2, which is found on many stomach cancer cells, and aims to help your immune system fight the cancer.
This early-phase trial tests a new type of immune cell therapy (TCRx T cells) for advanced stomach cancer that has not responded to standard chemotherapy. The goal is to see if these specially engineered cells can help your body fight the cancer.
This trial tests a special type of immune cell therapy for people with advanced gastric cancer. The treatment uses your own immune cells that are specially trained to find and attack cancer cells. It may help when standard treatments have stopped working.
Hear when a new Gastric (Stomach) Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.